Business Context and Reporting Period
This Form 8-K filing by Curis, Inc. reports a material definitive agreement entered into on June 19, 2006. The report was filed on August 29, 2006, covering the period from the agreement's effective date through the filing date.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific compensation terms of the new consulting agreement:
- Compensation Rate: $4,000 per day or $500 per hour.
- Aggregate Cap: $40,000 for the one-year term of the agreement.
Material Changes
The primary material change is the entry into a Consulting Agreement with Joseph M. Davie, Ph.D., M.D., a member of the Company's Board of Directors. Dr. Davie commenced services on June 19, 2006, providing expertise in corporate strategy, business development, drug development, and scientific leadership. The agreement was subject to Board approval, which was granted on August 23, 2006.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of general risks and contingencies. The agreement includes a termination clause allowing either party to end the contract with thirty days' written notice.
Investor Verification Checklist
- Verify the Board approval date of August 23, 2006, relative to the June 19, 2006 effective date.
- Confirm the total potential liability of $40,000 against the company's current cash position (not provided in this filing).
- Review the attached Exhibit 10.1 for any additional terms or conditions not summarized in the text.
- Assess the impact of Dr. Davie's dual role as a Board member and paid consultant on corporate governance.